ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice

Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

(2015) John M McPartland et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neural correlates of interactions between cannabidiol and Δ9-tetrahydrocannabinol in mice: implications for medical cannabis

(2015) S M Todd et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

(2015) R B Laprairie et al.   BRITISH JOURNAL OF PHARMACOLOGY

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

(2015) Stefan Wolking et al.   CLINICAL PHARMACOKINETICS

The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

(2015) Rishil J. Kathawala et al.   DRUG RESISTANCE UPDATES

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

Drug repurposing and emerging adjunctive treatments for schizophrenia

(2015) Jan Malte Bumb et al.   EXPERT OPINION ON PHARMACOTHERAPY

The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)

(2015) Kerstin Römermann et al.   NEUROPHARMACOLOGY

Cannabinoids and Epilepsy

(2015) Evan C. Rosenberg et al.   Neurotherapeutics

Cannabinoids in the Treatment of Epilepsy

(2015) Daniel Friedman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A systematic review of the antipsychotic properties of cannabidiol in humans

(2015) Tabitha A. Iseger et al.   SCHIZOPHRENIA RESEARCH

Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy

(2015) Famida G. Hoosain et al.   Biomed Research International

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

(2015) Maricla Galetti et al.   PLoS One

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

(2014) Young Choi et al.   CURRENT PHARMACEUTICAL DESIGN

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

(2014) Orrin Devinsky et al.   EPILEPSIA

The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs

(2014) Minzhi Li et al.   EPILEPSY RESEARCH

In vivo P-glycoprotein function before and after epilepsy surgery

(2014) M. Bauer et al.   NEUROLOGY

CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells

(2014) Jonathon C. Arnold et al.   Pharmacological Reports

Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting

(2014) Jennifer Johnston et al.   PSYCHOPHARMACOLOGY

Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study

(2013) Valeria Feinshtein et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy

(2013) Uzma Shaheen et al.   EPILEPSY RESEARCH

Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models

(2013) Haruka Nakanishi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Acetaminophen Inhibits Intestinal P-Glycoprotein Transport Activity

(2013) Analia Novak et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

P-glycoprotein expression and antiepileptic drug resistance

(2013) Jacqueline A French   LANCET NEUROLOGY

Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines

(2013) Valeria Feinshtein et al.   PeerJ

The Yin and Yang of Cannabis-induced Psychosis: the Actions of Δ 9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia

(2012) J. C. Arnold et al.   CURRENT PHARMACEUTICAL DESIGN

Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence

(2012) Leonora E. Long et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced byABCB1genotypes: a study from a south Indian perspective

(2012) Neetha N Vijayan et al.   PHARMACOGENOMICS

Enhanced Brain Disposition and Effects of Δ9-Tetrahydrocannabinol in P-Glycoprotein and Breast Cancer Resistance Protein Knockout Mice

(2012) Adena S. Spiro et al.   PLoS One

Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein

(2012) Tomoko Inoue et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

(2012) Nicholas A. Jones et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats

(2011) Charlotte Klein et al.   PSYCHOPHARMACOLOGY

In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein

(2010) Chunbo Zhang et al.   LIFE SCIENCES

Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia:

(2010) Onno L. de Klerk et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats

(2009) Alejandra M. Pacchioni et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice

(2009) Leonora E. Long et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo

(2009) N. A. Jones et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Schizophrenia

(2009) Jim van Os et al.   LANCET

Disposition of Δ9tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein

(2008) Laurence Bonhomme-Faivre et al.   ADDICTION BIOLOGY

Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia

(2008) Mary Bebawy et al.   BIOESSAYS

Several major antiepileptic drugs are substrates for human P-glycoprotein

(2008) Carlos Luna-Tortós et al.   NEUROPHARMACOLOGY

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

(2007) K KIRSCHBAUM   BEHAVIOURAL BRAIN RESEARCH

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids

(2007) M L Holland et al.   BRITISH JOURNAL OF PHARMACOLOGY

Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients

(2006) Nada Bozina et al.   JOURNAL OF PSYCHIATRIC RESEARCH